{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:16:02Z","timestamp":1781867762056,"version":"3.54.5"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: We investigated whether an incidental diagnosis (ID) of bladder cancer (BC) was associated with improved survival. Methods: We retrospectively reviewed data of consecutive patients with no prior diagnosis of urothelial cancer who underwent a primary transurethral resection of bladder tumor (pTURBT) between January 2013 and February 2021 and were subsequently diagnosed with urothelial BC. The type of diagnosis (incidental or non-incidental) was identified. Overall, relative, recurrence-free, and progression-free survival rates (OS, RS, RFS, and PFS) after pTURBT were evaluated using the Kaplan\u2013Meier curves and long-rank tests. A multivariable Cox regression model for the overall mortality was developed. Results: A total of 435 patients were enrolled. The median follow-up was 2.7 years. ID cases were more likely to be low-grade (LG) and non-muscle-invasive. ID vs. non-ID was associated with a trend toward an improved 7-year OS (66% vs. 49%, p = 0.092) and a significantly improved 7-year OS, if incidental cases were limited to ultrasound-detected tumors (75% vs. 49%, p = 0.013). ID was associated with improved survival among muscle-invasive BC (MIBC) patients (3-year RS: 97% vs. 23%, p &lt; 0.001), but not among other subgroups stratified according to disease stage or grade. In multivariable analysis, only age, MIBC, and high-grade (HG) cancer demonstrated an association with mortality. PFS and RFS among non-MIBC patients did not differ in regard to the type of diagnosis. Conclusions: Incidental diagnosis may contribute to an improved survival in BC patients, most probably in the mechanism of the relative downgrading of the disease, including the possible overdiagnosis of LG tumors. Nevertheless, in the subgroup analyses, we noted marked survival benefits in MIBC cases. Further prospective studies are warranted to gain a deeper understanding of the observed associations.<\/jats:p>","DOI":"10.3390\/cancers15030668","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T04:19:22Z","timestamp":1674447562000},"page":"668","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Incidental Diagnosis of Urothelial Bladder Cancer: Associations with Overall Survival"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8387-1474","authenticated-orcid":false,"given":"Hubert","family":"Kamecki","sequence":"first","affiliation":[{"name":"Department of Urogenital Cancer, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Second Department of Urology, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"D\u0119bowska","sequence":"additional","affiliation":[{"name":"Department of Computational Oncology, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Na\u0142\u0119cz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, 02-109 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8758-7200","authenticated-orcid":false,"given":"Jan","family":"Poleszczuk","sequence":"additional","affiliation":[{"name":"Na\u0142\u0119cz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, 02-109 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Demkow","sequence":"additional","affiliation":[{"name":"Department of Urogenital Cancer, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-8950","authenticated-orcid":false,"given":"Artur","family":"Przewor","sequence":"additional","affiliation":[{"name":"Department of Urogenital Cancer, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Nyk","sequence":"additional","affiliation":[{"name":"Second Department of Urology, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4894-4233","authenticated-orcid":false,"given":"Roman","family":"Sosnowski","sequence":"additional","affiliation":[{"name":"Department of Urogenital Cancer, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e004128","DOI":"10.1136\/bmjgh-2020-004128","article-title":"Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease study 2019","volume":"6","author":"Safiri","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non\u2013Muscle-invasive Stage Ta\u2013T1 Urothelial Bladder Cancer Patients Treated with 1\u20133 Years of Maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths, G., and Hall, R. (2011). International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J. Clin. Oncol., 29, 2171\u20132177.","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1586\/era.11.181","article-title":"Current treatment of metastatic bladder cancer and future directions","volume":"11","author":"Lei","year":"2011","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.eururo.2012.12.062","article-title":"Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives","volume":"63","author":"Catto","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1159\/000521684","article-title":"The Clinical Features of Incidentally Diagnosed Urothelial Bladder Cancer: A Retrospective Data Analysis","volume":"106","author":"Kamecki","year":"2022","journal-title":"Urol. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","article-title":"On Estimation in Relative Survival","volume":"68","author":"Perme","year":"2011","journal-title":"Biometrics"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wong, V., Ganeshan, D., Jensen, C., and Devine, C. (2021). Imaging and Management of Bladder Cancer. Cancers, 13.","DOI":"10.3390\/cancers13061396"},{"key":"ref_9","first-page":"417","article-title":"Comparison of bladder ultrasonographic and rigid cystoscopic findings in patients with hematuria","volume":"10","author":"Mostafaloo","year":"2019","journal-title":"Casp. J. Intern. Med."},{"key":"ref_10","first-page":"33.e7","article-title":"Active surveillance for low-risk bladder cancer","volume":"32","author":"Tiu","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.juro.2017.08.091","article-title":"Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project","volume":"199","author":"Hurle","year":"2018","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and Overtreatment of Prostate Cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-5347(17)36720-4","article-title":"A Community Study of Bladder Cancer Screening by the Detection of Occult Urinary Bleeding","volume":"148","author":"Britton","year":"1992","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/cncr.22224","article-title":"Long-term outcome of hematuria home screening for bladder cancer in men","volume":"107","author":"Messing","year":"2006","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00043764-199009000-00021","article-title":"Bladder Cancer Screening among Primary Aluminum Production Workers in Quebec","volume":"32","author":"Tremblay","year":"1990","journal-title":"J. Occup. Environ. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1464-410X.2008.07789.x","article-title":"The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22","volume":"102","author":"Raina","year":"2008","journal-title":"BJU Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00043764-199009000-00020","article-title":"Screening Workers Exposed to 4,4??- Methylenebis(2-chloroaniline) for Bladder Cancer by Cystoscopy","volume":"32","author":"Ward","year":"1990","journal-title":"J. Occup. Environ. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.13154","article-title":"Long-term outcomes in a high-risk bladder cancer screening cohort","volume":"117","author":"Starke","year":"2015","journal-title":"BJU Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ajim.10166","article-title":"The Drake Health Registry Study: Findings from fifteen years of continuous bladder cancer screening","volume":"43","author":"Marsh","year":"2003","journal-title":"Am. J. Ind. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00420-013-0916-3","article-title":"Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines","volume":"87","author":"Pesch","year":"2013","journal-title":"Int. Arch. Occup. Environ. Heal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/JOM.0000000000000377","article-title":"Bladder Cancer Screening in Aluminum Smelter Workers","volume":"57","author":"Taiwo","year":"2015","journal-title":"J. Occup. Environ. Med."},{"key":"ref_22","first-page":"686","article-title":"Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project)","volume":"28","author":"Roobol","year":"2010","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1464-410X.2008.07596.x","article-title":"Early results of bladder-cancer screening in a high-risk population of heavy smokers","volume":"102","author":"Steiner","year":"2008","journal-title":"BJU Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5455\/aim.2011.19.168-171","article-title":"Application of Ultrasound in Medicine","volume":"19","author":"Carovac","year":"2011","journal-title":"Acta Inform. Medica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1259\/bjr\/43400531","article-title":"Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer","volume":"84","author":"Nicolau","year":"2011","journal-title":"Br. J. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4149\/neo_2016_420","article-title":"Stage of bladder cancer in Central Europe: Polish perspective","volume":"63","author":"Poletajew","year":"2016","journal-title":"Neoplasma"},{"key":"ref_27","first-page":"152","article-title":"Diagnostic and treatment delays among patients with primary bladder cancer in Poland: A survey study","volume":"73","author":"Mielczarek","year":"2020","journal-title":"Central Eur. J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.3399\/bjgp14X681409","article-title":"Non-visible versus visible haematuria and bladder cancer risk: A study of electronic records in primary care","volume":"64","author":"Price","year":"2014","journal-title":"Br. J. Gen. Pr."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/668\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:13:02Z","timestamp":1760119982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15030668"],"URL":"https:\/\/doi.org\/10.3390\/cancers15030668","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]}}}